Quartet lags Lyra and Cerebral
Quartet Health
This gap shows that Quartet built depth in one workflow, while rivals widened the number of ways they could win members and budgets. Quartet’s core product is a referral and matching layer for payers and health systems. It finds at risk patients through claims, EHR data, and primary care referrals, then routes them to in network mental health providers. Lyra and Cerebral expanded faster into coaching, therapy, medication, and more direct patient entry points, which gave them more surfaces to acquire users and grow revenue.
-
Quartet’s original model is operationally heavy. It sells to insurers, onboards provider networks, integrates with Epic and Cerner, and depends on primary care referrals for about 80% of patients. That creates strong payer fit, but every new product has to work inside insurer and provider workflows, which slows launch speed.
-
Lyra and Cerebral shipped broader care bundles earlier. Lyra added coaching, therapy, and medication management for employer populations. Cerebral built a consumer subscription flow around online intake, therapy, and prescribing. Those models let them test and launch new services faster because they control the front door instead of waiting on payer contracts and referrals.
-
The market rewarded breadth for a time. Lyra reached about $200M of revenue and a $5.5B valuation, while Cerebral scaled nationally with more than 200,000 patients. Quartet remained smaller at an estimated $49.7M in 2021, which made product expansion more important because growth could not rely on geography alone.
Going forward, the path is to turn Quartet’s matching engine into a broader behavioral health operating layer. That is already the direction of travel under NeuroFlow, which combined Quartet’s referral network with analytics and measurement products. The winning platforms in this market will not just find a therapist, they will identify risk, route care, measure outcomes, and give payers one system to manage the whole workflow.